Completed PHASE3 INTERVENTIONAL 2-arm NCT00836693

Effect of Tadalafil Once a Day in Men With Erectile Dysfunction

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors

Sponsor: Eli Lilly and Company

Conditions Erectile Dysfunction

Interventions placebo tadalafil

Updated 7 times since 2017 Last updated: Dec 15, 2010 Started: Jan 31, 2009 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00836693, this PHASE3 trial focuses on Erectile Dysfunction and remains completed. Sponsored by Eli Lilly and Company, it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aravaca, Spain , Athens, Greece , Bad Wiessee, Germany , Barcelona, Spain , Berlin, Germany , Bialystok, Poland , Catania, Italy , Florence, Italy , Hamburg, Germany , Koblenz, Germany and 11 more locations